UNSPSC 51241106: Demecarium

This classification denotes an anti-glaucoma agent and acetylcholinesterase inhibitor with the molecular formula C32H52N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61D5V4OKTP, chemically known as n,n-bis(3-trimethylammoniumphenoxycarbonyl)-n,n-dimethyldecamethylenediamine dibromide but generally known as demecarium bromide, which bears US NIH Compound Identifier 5965. European Medicines Agency schedules Demecarium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06962MIG.

UNSPSC 51241106 Demecarium, a Commodity code, covers generic pharmaceutical products and over-the-counter medicinal compounds procured by state and local health systems, cooperative purchasing alliances, and participating government facilities. State and local buyers use this code to source individual pharmaceutical active ingredients and finished generic medications distributed through established pharmaceutical wholesalers under framework agreements that specify pricing, product availability, manufacturing compliance, and supply-chain security requirements. The typical issuing body is a multistate cooperative purchasing organization or a state health department acting on behalf of multiple participating jurisdictions; individual state facilities and local government health systems purchase under established blanket contracts rather than issuing standalone solicitations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the standout active buyer in this code space. MMCAP issued a Request for Proposal (RFP) on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon. The procurement requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and to maintain contractual relationships with at least two of the three, with pricing weighted at 75 percent of the evaluation, compliance and administrative capability at 20 percent, and fixed pricing and EDI capability at the remainder. Vendors must certify cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain comprehensive insurance including $5,000,000 commercial general liability coverage, and agree to a 3 percent administrative fee on all purchases. The contract term is two years for new responders with optional extensions, and awarded vendors will be provided to wholesalers by May 15, 2026 with resulting agreements effective July 1, 2026.